Yonsei Med J.  2016 Nov;57(6):1508-1510. 10.3349/ymj.2016.57.6.1508.

Is Multi-Drug Resistant Tuberculosis More Prevalent in HIV-Infected Patients in Korea?

• Lee S
• Lee SH
• Mok JH
• Lee SJ
• Kim KH
• Lee JE
• Lee SG
• Chung JS
• Kwak IS

• KMID: 2427172
• DOI: http://doi.org/10.3349/ymj.2016.57.6.1508

Abstract

The epidemiological synergy between human immunodeficiency virus (HIV) and tuberculosis (TB) is a major threat to public health. However, the association between HIV and multi-drug resistant tuberculosis (MDR-TB) is not clear. To explore the association between HIV and MDR-TB infection, a case-control study was performed in Korea. A total of 1606 culture-proven TB patients (45 HIV vs. 1561 non-HIV) from January 2006 to October 2014 were included in this analysis. MDR-TB rates were 11.1% and 8.2% in the HIV and non-HIV groups, respectively (p=0.42), thus indicating that MDR-TB was not significantly associated with HIV infection in Korea.

Keyword

MDR; HIV; resistance; intermediate TB burden

MeSH Terms

Adult
Antitubercular Agents/therapeutic use
Case-Control Studies
Coinfection
Female
HIV Infections/*complications/drug therapy/*epidemiology/microbiology
Humans
Male
Middle Aged
Mycobacterium tuberculosis/drug effects/isolation & purification
Prevalence
Republic of Korea/epidemiology
Tuberculosis, Multidrug-Resistant/complications/*epidemiology/microbiology
Tuberculosis, Pulmonary/diagnosis/drug therapy/epidemiology
Antitubercular Agents

Reference

1. World Health Organization. Global tuberculosis report. WHO/HTM/TB/2015.22. Geneva: World Health Organization;2015.

2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163:1009–1021.

3. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011; 24:351–376.

4. Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, Huaroto L, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg. 2006; 75:1027–1033.

5. Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014; 9:e82235.

6. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007; 196 Suppl 1:S86–S107.

7. Lee SH, Seo KA, Lee YM, Lee HK, Kim JH, Shin C, et al. Low serum concentrations of moxifloxacin, prothionamide, and cycloserine on sputum conversion in multi-drug resistant TB. Yonsei Med J. 2015; 56:961–967.

8. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: World Health Organization;2014.

9. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014). WHO/HTM/TB/2013.2. Geneva: World Health Organization;2013.

10. Joh JS, Hong HC, Jeong IA, Chin BS, Yang HJ, Choi H, et al. Proportion of multidrug-resistant tuberculosis in human immunodeficiency virus/mycobacterium tuberculosis co-infected patients in Korea. J Korean Med Sci. 2012; 27:1143–1146.

11. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg HM, Kempker RR. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014; 59:1559–1566.